Novel lymphoid enhancer-binding factor 1-cytoglobin axis promotes extravasation of osteosarcoma cells into the lungs.
Mongkol PongsuchartTakahiro KuchimaruSakiko YonezawaDiem Thi Phuong TranNguyen The KhaNgoc Thi Hong HoangTetsuya KadonosonoShinae Kizaka-KondohPublished in: Cancer science (2018)
Lung metastasis is a major cause of mortality in patients with osteosarcoma (OS). A better understanding of the molecular mechanism of OS lung metastasis may facilitate development of new therapeutic strategies to prevent the metastasis. We have established high- and low-metastatic sublines (LM8-H and LM8-L, respectively) from Dunn OS cell line LM8 by using in vivo image-guided screening. Among the genes whose expression was significantly increased in LM8-H compared to LM8-L, the transcription factor lymphoid enhancer-binding factor 1 (LEF1) was identified as a factor that promotes LM8-H cell extravasation into the lungs. To identify downstream effectors of LEF1 that are involved in OS lung metastasis, 13 genes were selected based on LM8 microarray data and genomewide meta-analysis of a public database for OS patients. Among them, the cytoglobin (Cygb) gene was identified as a key effector in promoting OS extravasation into the lungs. CYGB overexpression increased the extravasation ability of LM8-L cells, whereas knocking out the Cygb gene in LM8-H cells reduced this ability. Our results showed a novel LEF1-CYGB axis in OS lung metastasis and may provide a new way of developing therapeutic strategies to prevent OS lung metastasis.
Keyphrases
- transcription factor
- induced apoptosis
- cell cycle arrest
- genome wide
- genome wide identification
- binding protein
- healthcare
- small cell lung cancer
- squamous cell carcinoma
- cell death
- cell proliferation
- signaling pathway
- cardiovascular disease
- newly diagnosed
- chronic kidney disease
- regulatory t cells
- poor prognosis
- cardiovascular events
- type diabetes
- emergency department
- prognostic factors
- mesenchymal stem cells
- electronic health record
- pi k akt
- patient reported outcomes
- cell therapy
- bioinformatics analysis